Levobupivacaina Kabi

Levobupivacaine, the active ingredient in Levobupivacaina Kabi, is a local anesthetic presented as a sterile solution for epidural use. It provides analgesia for epidural anesthesia, postoperative pain control, and labor analgesia. GNH USA supplies Levobupivacaina Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levobupivacaina Kabi is a local anesthetic used in the epidural pathway to manage pain and provide surgical anesthesia. - Epidural anesthesia: produces surgical anesthesia for procedures requiring nerve block via the epidural space. - Post‑operative analgesia: delivers effective pain relief after surgery to reduce opioid requirements. - Labor analgesia: offers controlled pain management during childbirth while preserving maternal consciousness.

Adverse reactions may occur with levobupivacaine administration.

Common Side Effects: - Hypotension: decreased blood pressure following epidural injection. - Bradycardia: slowed heart rate observed during or after dosing. - Nausea: feeling of sickness or urge to vomit. - Pruritus: localized itching, often around the injection site. - Dizziness: sensation of light‑headedness or unsteadiness.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm that can be life‑threatening. - Seizures: convulsive activity due to central nervous system toxicity. - Respiratory depression: reduced breathing effort requiring ventilatory support.

When using Levobupivacaina Kabi, clinicians should observe several safety measures. - Dose determination: individualized by the anesthesiologist based on patient weight, age, and procedure. - Cardiovascular monitoring: continuous observation for hypotension, bradycardia, or arrhythmias. - Neurological assessment: watch for signs of spinal cord toxicity or prolonged numbness. - Allergy history: confirm no known hypersensitivity to amide‑type local anesthetics. - Pregnancy and lactation: use only when the expected benefit justifies potential risk. - Store below 25°C: keep in the original container, protect from light and moisture.

Levobupivacaina Kabi may interact with other medications, requiring careful management.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine): increase risk of cardiotoxicity. - Beta‑blockers: may exacerbate bradycardia and hypotension. - General anesthetics (e.g., propofol): additive central nervous system depression.

Moderate Interactions (Monitor Closely): - Opioids: enhanced sedation and respiratory depression. - NSAIDs: potential increase in bleeding tendency. - Magnesium sulfate: potentiation of neuromuscular blockade.